YPSN Stock Overview
Develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Ypsomed Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 320.00 |
| 52 Week High | CHF 439.00 |
| 52 Week Low | CHF 261.00 |
| Beta | 1.12 |
| 1 Month Change | -3.32% |
| 3 Month Change | -1.39% |
| 1 Year Change | -17.42% |
| 3 Year Change | 114.19% |
| 5 Year Change | 144.27% |
| Change since IPO | 332.43% |
Recent News & Updates
Shareholders Should Be Pleased With Ypsomed Holding AG's (VTX:YPSN) Price
Apr 12
What Does Ypsomed Holding AG's (VTX:YPSN) Share Price Indicate?
Feb 23We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt
Jan 23Recent updates
Shareholders Should Be Pleased With Ypsomed Holding AG's (VTX:YPSN) Price
Apr 12What Does Ypsomed Holding AG's (VTX:YPSN) Share Price Indicate?
Feb 23We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt
Jan 23Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
Jan 09Returns On Capital Are Showing Encouraging Signs At Ypsomed Holding (VTX:YPSN)
Dec 23
GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins
Dec 07 Ypsomed's shift to a B2B model and local manufacturing may streamline operations, improve focus, and reduce geopolitical risks, enhancing margins and earnings.We Think That There Are Some Issues For Ypsomed Holding (VTX:YPSN) Beyond Its Promising Earnings
Nov 20Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Interim Results
Nov 17Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
Aug 13There Are Reasons To Feel Uneasy About Ypsomed Holding's (VTX:YPSN) Returns On Capital
Jul 31If EPS Growth Is Important To You, Ypsomed Holding (VTX:YPSN) Presents An Opportunity
Jul 03Here's Why Ypsomed Holding AG's (VTX:YPSN) CEO May Deserve A Raise
Jun 19Should You Investigate Ypsomed Holding AG (VTX:YPSN) At CHF395?
Jun 10Here's What Analysts Are Forecasting For Ypsomed Holding AG (VTX:YPSN) After Its Full-Year Results
May 25Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
May 08Shareholder Returns
| YPSN | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 4.1% | 3.4% | 1.2% |
| 1Y | -17.4% | -13.4% | -3.2% |
Return vs Industry: YPSN underperformed the Swiss Medical Equipment industry which returned -12.6% over the past year.
Return vs Market: YPSN underperformed the Swiss Market which returned -2.9% over the past year.
Price Volatility
| YPSN volatility | |
|---|---|
| YPSN Average Weekly Movement | 5.0% |
| Medical Equipment Industry Average Movement | 4.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in CH Market | 8.5% |
| 10% least volatile stocks in CH Market | 2.4% |
Stable Share Price: YPSN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: YPSN's weekly volatility (5%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,600 | Simon Michel | www.ypsomed.com |
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices.
Ypsomed Holding AG Fundamentals Summary
| YPSN fundamental statistics | |
|---|---|
| Market cap | CHF 4.37b |
| Earnings (TTM) | CHF 74.39m |
| Revenue (TTM) | CHF 617.07m |
58.7x
P/E Ratio7.1x
P/S RatioIs YPSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YPSN income statement (TTM) | |
|---|---|
| Revenue | CHF 617.07m |
| Cost of Revenue | CHF 398.41m |
| Gross Profit | CHF 218.66m |
| Other Expenses | CHF 144.28m |
| Earnings | CHF 74.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
May 21, 2025
| Earnings per share (EPS) | 5.45 |
| Gross Margin | 35.44% |
| Net Profit Margin | 12.05% |
| Debt/Equity Ratio | 52.3% |
How did YPSN perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield37%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 04:08 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ypsomed Holding AG is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Curtis Moiles | BNP Paribas Exane |
| Marianne Bulot | BofA Global Research |